Since COVID-19 hit, many industries have shifted a heavier weighting of their business into the online world, relying on e-commerce and digital engagement to counterbalance the reduced abil
Given the recent rise in digital engagement and the drastic increase in digital content, it’s now essential that pharmaceutical companies have a comprehensive content strategy.
Sarah Rickwood delves into IQVIA data to find out exactly how pharma's HCP engagement has changed over COVID-19, and what the channel mix might look like after the pandemic.
The boom in digital tech over COVID means that pharma can move faster than ever – but the industry’s traditional processes for asset approval are still holding timelines back.
A few months into the pandemic, the world is now moving beyond managing the crisis, with more focus on addressing the collateral damages and shaping the future.
For a long time, venture capital (VC) firms have been controlled mainly by men. But things are changing and women are becoming more influential in life sciences VCs, with an increase in bu
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.